Palomino Laboratories Inc. 8-K

What Happened
Palomino Laboratories, Inc. (PALX) filed an 8‑K on April 24, 2026 reporting that it entered into material definitive agreements related to a subscription and related registration‑rights arrangements. The filing also discloses unregistered sales of equity securities tied to those agreements. The company filed the forms of the Subscription Agreement and Registration Rights Agreements as exhibits.

Key Details

• Filing date: April 24, 2026 (Form 8‑K). Items reported: 1.01 (Entry into a Material Definitive Agreement) and 3.02 (Unregistered Sales of Equity Securities).
• Exhibits filed: Form of Subscription Agreement (Exhibit 4.1*), Form of Registration Rights Agreement (Exhibit 10.1), and Form of Laidlaw Registration Rights Agreement (Exhibit 10.2).
• The description in the 8‑K is qualified by the actual agreement forms filed as exhibits; certain schedules to the Subscription Agreement were omitted per Item 601(a)(5) of Regulation S‑K and are available to the SEC on request.
• The filing does not disclose dollar amounts, number of securities issued, or other economic terms in the 8‑K text provided.

Why It Matters
Agreements like subscription and registration‑rights pacts typically relate to capital raises and the future registration of shares for resale. For investors, this can mean potential dilution if new shares are being issued and the establishment of registration rights that may result in future public filings to register those shares. The unregistered sales note indicates securities were issued under an exemption rather than through an immediate SEC registration. Because the 8‑K does not include amounts or share counts, investors should review the actual agreement exhibits (or subsequent filings) for the specific financial terms and any impact on share count or voting power.